Helen Liang combines a PhD with more than ten years of product and operations experience, and she invests across the full range of AI—from chips and robotics to AI agents and biology—work that has led TechCrunch to invite her twice to speak on robotics and AI panels about her early-stage investments in the space. She also sits on the board of Cognito Therapeutics, which is developing a non-drug treatment for Alzheimer's, and advises U.S. startups on China's AI opportunities through the CKGSB Chuang Silicon Valley Program.